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Infection of red blood cells by Plasmodium species induces clinical malaria, a devastating global health problem that has been exacerbated by the emergence of drug-resistant parasites 1, 2 . Thus, new approaches to combat malaria, such as effective vaccines or other immune interventions, are much needed. Given the clear correlation between high parasite density and disease severity in children 3 , much effort has gone into developing vaccines that target the blood stage of Plasmodium infection, with the goal of diminishing the morbidity and mortality of malaria. However, success has been limited, and candidate subunit vaccines in clinical trials have not proven highly efficacious thus far 4, 5 , although studies of killed blood-stage parasites and specific adjuvant show promise in mouse models 6 . One reason for the limited progress in antimalarial vaccination probably relates to incomplete understanding of how the parasite evades adaptive immunity and the specific characteristics of the cellular immune responses that mediate protection against blood-stage Plasmodium infection. Whereas it is well understood from clinical human correlates 7 -9 and experimental rodent models 10 -13 that CD4 + T cells are a critical component of the protective immune responses that arise after exposure to blood-stage Plasmodium parasites, very little is known about how Plasmodiumspecific CD4 + T cell responses influence the balance between parasite clearance and persistent blood-stage infection. Additionally, whether or how blood-stage Plasmodium infection influences the development of CD4 + follicular helper T cell (T FH cell) responses, with subsequent and direct effects on humoral immunity, remains undefined.
In humans who survive infection with Plasmodium falciparum without treatment, parasites can be detected in the blood for several weeks or months 14 and can also establish a chronic recrudescent bloodstage infection that can persist for years 15 -17 . The former scenario is mimicked in mouse models by Plasmodium yoelii , which establishes patent infections that last 30 d in immunocompetent hosts, whereas the latter feature is mimicked by Plasmodium chaubadi , which can establish persistent, subpatent infections that last for several months 18 . Of note, chronic viral infection in humans, such as infection with human immunodeficiency virus or hepatitis C virus, drives the functional exhaustion of antiviral T cells 19 -21 , a phenomenon first described for CD8 + T cells in mice chronically infected with lymphocytic choriomeningitis virus (LCMV) clone 13 (ref. 22) . In the mouse LCMV model, repeated antigen stimulation through the T cell antigen receptor drives the sustained expression of T cell inhibitory receptors, including PD-1 and LAG-3, on virus-specific CD8 + T cells. Sustained signaling through these inhibitory receptors directly and indirectly induces transcriptional changes that negatively regulate proliferation and the expression of proinflammatory cytokines by virus-specific CD8 + T cells 23, 24 . On the basis of such observations, we tested the hypothesis that humans exposed to P. falciparum would have CD4 + T cells with phenotypic characteristics of T cell exhaustion and that therapeutic blockade of signaling via T cell inhibitory receptors in vivo would markedly improve clinical outcomes in models of rodent malaria.
RESULTS

Plasmodium infection induces T cell exhaustion
To identify potential relationships between P. falciparum infection and exhaustion of circulating CD4 + T cells, we focused on a cohort study in Mali, where P. falciparum transmission is intense and seasonal 25 and occurs during the 6-month rainy period from July through December. Study participants were children 5 -11 years of age who were analyzed at two time points: at the end of the dry season when they had a blood smear negative for P. falciparum (before malaria) and again 7 d after the diagnosis and treatment of the first symptomatic P. falciparum infection of the malaria season (after malaria; Fig. 1a ). Consistent with our hypothesis, we observed higher frequencies of PD-1-expressing CD4 + T cells in children after infection with P. falciparum ( Fig. 1a and Supplementary Fig. 1 ), which suggested that P. falciparum infection is associated with expression of the T cell inhibitory receptor PD-1 on CD4 + T cells in people with clinical malaria.
To address the biological relevance of those data, we turned to mouse models of blood-stage malaria. Initially we focused on the prolonged blood-stage infection ( > 30 d) induced by injection of mice with parasitized red blood cells (pRBCs) containing the normally nonlethal P. yoelii strain 17XNL. Studies of mice depleted of T cells suggested a critical role for CD4 + T cells in survival after challenge with red blood cells infected with P. yoelii ( P. yoelii pRBCs; Fig. 1b ). Additionally, mice deficient in the cytidine deaminase AID ( Aicda − / − ) with additional deletion of the immunoglobulin heavy-chain μ -secretory domain, which have mature B cells positive for immuno globulin M (IgM) but cannot undergo isotype switching or secrete antibodies, also succumbed to blood-stage P. yoelii infection ( Fig. 1b ). Although not conclusive, these data were consistent with a critical role for secreted antibody in survival after challenge with P. yoelii pRBCs. Of note, the paucity of identified epitopes has hampered efforts to define the precise characteristics of CD4 + T cells that either determine protection or correlate with persistent blood-stage Plasmodium infection. A surrogate-activation-marker approach has been used to evaluate the total CD8 + T cell response to attenuated whole-Plasmodium sporozoite vaccines 26 . This approach allows monitoring of the total CD8 + T cell response to infection or vaccination in the absence of information about major histocompatibility complex (MHC) restriction, epitopes or antigens 27 . To test our hypothesis, we applied a modified surrogateactivation-marker approach that relies on co ordinated upregulation of the integrins CD49d and CD11a on antigen-experienced CD4 + T cells to directly identify Plasmodium -specific CD4 + T cells responding to blood-stage infection. The utility of this approach has been extensively confirmed for viral infection 28 , and we further confirmed it by examining the expression patterns of CD49d and CD11a on CD4 + T cells of known specificity induced by infection with LCMV or Listeria monocytogenes . Indeed, all LCMV epitope -specific or Supplementary Fig. 2a,b ). Of note, because not all CD4 + T cells responding to LCMV or L. monocytogenes were specific for the two dominant epitopes examined (glycoprotein amino acids 61 -80 (LCMV) or listeriolysin O amino acids 190 -201 ( L. monocytogenes )), and some antigen-specific CD4 + T cells may express cytokines other than IFN-γ , not all CD49d hi CD11a hi T cells expressed IFN-γ in these assays ( Supplementary Fig. 2a,b ). Naive C57BL / 6 mice had a small fraction ( ~ 1 % ) of CD49d hi CD11a hi circulating CD4 + T cells before infection; however, infection of C57BL / 6 mice with P. yoelii pRBCs resulted in the appearance of a large population ( > 20 % ) of circulating CD49d hi CD11a hi CD4 + T cells by day 7 after infection ( Fig. 1c ). Notably, expression of the CD49d hi CD11a hi phenotype by CD4 + T cells required crosslinking of T cell antigen receptors and was not a result of Plasmodium -induced inflammation because naive transgenic CD4 + T cells specific for LCMV (SMARTA CD4 + T cells (with a T cell antigen receptor specific for LCMV glycoprotein amino acids 61 -80)) 29 did not upregulate CD49d or CD11a expression during blood-stage P. yoelii infection ( Supplementary Fig. 2c ). To address the specificity of these markers at the memory phase, we adoptively transferred purified P. yoeliispecific CD49d hi CD11a hi memory CD4 + T cells or CD49d lo CD11a lo naive CD4 + T cells (both obtained > 70 d after infection from mice that had cleared P. yoelii infection) into naive, allelically marked recipient mice. Notably, infection of recipient mice with P. yoelii resulted in secondary T cell population expansion only of transferred CD49d hi CD11a hi memory cells but not of CD49d lo CD11a lo naive CD4 + T cells ( Supplementary Fig. 2d,e ). Thus, the CD49d hi CD11a hi phenotype faithfully and durably identified Plasmodium -specific effector and memory CD4 + T cells.
By the approach described above, we determined that infection of mice with P. yoelii resulted in substantial CD4 + T cell responses and that these cells showed sustained proliferation over the course of the 30-day period of patent blood-stage infection ( Fig. 1d ). By day 30 after infection, we also observed that a large fraction ( > 25 -40 % ) of P. yoelii -specific CD49d hi CD11a hi CD4 + T cells expressed the T cell inhibitory receptors PD-1 and LAG-3, similar to CD4 + T cells responding to chronic LCMV infection ( Fig. 1e ). Of note, the frequency of total CD4 + T cells expressing PD-1 was similar in P. yoeliiinfected mice ( ~ 3.75 % ) and P. falciparum -infected humans ( ~ 3.5 % ; Fig. 1a ). Furthermore, and consistent with their exhausted phenotype, P. yoelii -specific CD4 + T cells also showed impaired production of cytokines (IFN-γ , tumor necrosis factor and interleukin 2) in response to stimulation with the phorbol ester PMA plus ionomycin relative to that of virus-specific CD4 + T cells from mice either acutely or chronically infected with LCMV on day 31 after infection ( Fig. 1f ). Additionally, parasite-specific CD8 + T cells (identified by lower cell surface expression of the monomorphic coreceptor CD8 α and higher cell surface expression of CD11a (ref. 27 )) showed sustained proliferation throughout the infection and both the phenotypic and functional characteristics of T cell exhaustion at day 30 after infection ( Supplementary Fig. 3 ). Collectively, these data showed that prolonged blood-stage infection with Plasmodium elicited dysfunctional parasite-specific T cells, including the critical CD4 + T cell subset required for eventual clearance of infection.
Prolonged infection leads to T cell exhaustion
To directly evaluate whether prolonged blood-stage Plasmodium infection was responsible for the appearance of dysfunctional populations of T cells in mice with clinical malaria, we used groups of mice with matched blood-stage P. yoelii infection and treated them with injections of chloroquine or vehicle control (PBS) on days 8 and 9 after infection. Two successive treatments with chloroquine resulted in a rapid and substantial decrease in parasite burden without complete parasite clearance (data not shown). We found that ~ 60 % of ex vivo -stimulated, parasite-specific CD49d hi CD11a hi CD4 + T cells expressed IFN-γ at day 8 after infection ( Fig. 2a ). The capa city to produce IFN-γ was lowered to ~ 15 % of parasite-specific CD4 + T cells by day 24 after infection in PBS control mice; however, chloro quine treatment to diminish parasitemia partially restored IFN-γ production ( Fig. 2b ). It also partially reversed the exhausted phenotype at day 24 after infection, with ~ 40 % or ~ 70 % lower fractions of parasite-specific CD4 + T cells expressing PD-1 or LAG-3, respectively ( Fig. 2b ) . Similarly, chloroquine treatment resulted in a lower fraction of CD8 + T cells expressing inhibitory receptors and a greater fraction of CD8 + T cells able to produce cytokines ( Supplementary Fig. 4 ). Notably, these data also demonstrated distinct phenotypic differences between CD4 + T cells and CD8 + T cells undergoing functional exhaustion during chronic infection, as we observed upregulation of the inhibitory receptors CD160 and 2B4 only on exhausted CD8 + T cells ( Supplementary Fig. 4 and data not shown). Collectively, these data indicated that prolonged blood-stage P. yoelii infection elicited the phenotypic and functional npg attributes of parasite-specific T cell exhaustion. They also showed that specific functional attri butes of parasite-specific T cells (such as the ability to express IFN-γ ) progressively deteriorated during prolonged blood-stage Plasmodium infection.
Blockade of PD-L1 and LAG-3 clears blood-stage malaria
PD-1 interacts with its ligands PD-L1 and PD-L2 and, in addition, PD-L1 can interact with the costimulatory molecule CD80 (refs. 30, 31) . LAG-3 mediates negative regulation through interactions with MHC class II (refs. 32, 33 ) . Notably, synergistic blockade of interactions with T cell inhibitory receptors improves CD8 + T cell function and virus control during chronic LCMV cl13 infection 24 . Thus, to address the biological role of T cell inhibitory receptors expressed by parasite-specific T cells during prolonged blood-stage Plasmodium infection, we administered nondepleting monoclonal antibodies (anti-PD-L1 and anti-LAG-3) that prevent the inhibitory receptors PD-1 and LAG-3 from functionally engaging their major ligands (PD-L1 and MHC class II, respectively) 23, 24, 33 . To mimic therapeutic intervention of clinical malaria, we gave mice with matched large parasite burdens ( ~ 25 -30 % of RBCs contained parasites) at day 14 after infection regular injections of anti-PD-L1 and anti-LAG-3, or rat IgG as a control, and monitored clearance of parasites from the blood. We observed that blockade of PD-L1 and LAG-3 resulted in immediate control of parasite burdens and substantially accelerated parasite clearance ( Fig. 3a ), which correlated with many more parasite-specific CD4 + T cells ( Fig. 3b ) and restoration of parasite-specific CD4 + T cell cytokine responses ( Fig. 3c,d ).
Blockade of PD-L1 and LAG-3 similarly restored both numerical and functional features of parasite-specific CD8 + T cell responses ( Supplementary Fig. 5 ). However, therapeutic blockade of PD-L1 and LAG-3 failed to improve parasite clearance in mice depleted of CD4 + T cells or Aicda − / − mice lacking the immunoglobulin heavychain μ -chain secretory domain (data not shown), consistent with a critical role for the CD4 + T cell -B cell axis in parasite control. Of note, blockade with anti-PD-L1 alone had a partial effect on parasite clearance, whereas anti-LAG-3 alone minimally influenced bloodstage infection but instead acted synergistically with anti-PD-L1 to accelerate parasite clearance ( Supplementary Fig. 6 ). Collectively, these data showed markedly enhanced parasite control during blood-stage infection with Plasmodium after therapeutic blockade of PD-L1 and LAG-3. Additionally, these data suggested that PD-L1 and LAG-3, as well as their respective ligand-receptor interactions, acted synergistically to inhibit T cell responses during persistent blood-stage Plasmodium infection. 
Blockade of PD-L1 and LAG-3 prevents chronic infection
To address whether the improved clinical outcomes after therapeutic blockade of PD-L1 and LAG-3 were system specific ( P. yoelii and C57BL / 6 mice) or could be generalized, we next evaluated clinical efficacy in outbred Swiss Webster mice, which more closely mimic the genetic complexity of humans. Therapeutic blockade of PD-L1 and LAG-3 also resulted in a rapid decrease in parasitemia and accelerated clearance of P. yoelii blood-stage infection in outbred Swiss Webster mice ( Fig. 4a ), which suggested that both T cell exhaustion and successful therapeutic blockade of blockade of PD-L1 and LAG-3 were independent of host genetic background and the targeted parasite antigens or epitopes. Additionally, we evaluated the effect of blockade of PD-L1 and LAG-3 on the clinical course of infection with Plasmodium chabaudi chabaudi ( P. chabaudi ), a malaria parasite known to establish long-term, subpatent infections in mice, as determined by the ability of transferred blood to establish new infections in naive mice 34 -36 . The rationale for extending our studies to the P. chabaudi model was to address the effect of the blockade of inhibitory receptors on the clearance of persisting malaria parasites that are undetectable by blood smear, an important aspect of human malaria that is not recapitulated in the P. yoelii model. For those reasons, blood-stage infection of rodents with P. chabaudi is considered to be the small-animal model that most closely resembles persistent blood-stage Plasmodium infection in humans. Therapeutic blockade of PD-L1 and LAG-3 initiated at day 14 after infection did not have a discernable effect on clearance of patent blood-stage P. chabaudi infection in C57BL / 6 mice ( Fig. 4b ). Of note, neither control mice treated with rat IgG nor mice treated by blockade of PD-L1 and LAG-3 showed detectable recrudescence of P. chabaudi on days 18 -30 or on day 40 (limit of detection of parasitemia, < 0.02 % ). However, blockade of PD-L1 and LAG-3 resulted in the complete elimination of persistent, subpatent P. chabaudi infection in most mice, as determined by the failure of whole-blood transfer to initiate blood-stage infection, which we observed for 100 % of recipient mice that received blood from P. chabaudi -infected mice treated with rat IgG ( Fig. 4c ). Collectively, these data showed that the clinical benefits of therapeutic blockade of PD-L1 and LAG-3 could be generalized to outbred rodents and occurred independently of host immunogenetics and Plasmodium parasite species. Moreover, these data indicated that blockade of PD-L1 and LAG-3 induced sterilizing immunity even to low-grade, subpatent Plasmodium infection.
Blockade of PD-L1 and LAG-3 enhances T FH and plasma cells
Given our results suggesting a critical role for the CD4 + T cell -B cell axis in clearance of blood-stage Plasmodium infection ( Fig. 1b and data not shown), as well as published data showing modestly enhanced humoral immunity after in vivo PD-1 blockade 37, 38 , we next evaluated the mechanistic effects of blockade of PD-L1 and LAG-3 on CD4 + T FH cells, which regulate germinal-center B cell reactions necessary for the generation of high-affinity antibody responses 39 . Of note, blood-stage infection with P. yoelii resulted in the induction of CD150 lo CXCR5 + T FH cells ( Fig. 5a ), as has been reported after chronic LCMV infection of mice 40 . However, blockade of PD-L1 and LAG-3 in P. yoeliiinfected mice resulted in a doubling of the frequency of T FH CD4 + T cells ( Fig. 5a ), which correlated with an increase of over 15-fold in the frequency of plasmablasts (CD19 lo B220 lo CD138 hi IgD − ; Fig. 5b ). In all, blockade of PD-L1 and LAG-3 resulted in sevenfold more total T FH CD4 + T cells and 50-fold more plasmablasts in P. yoelii -infected mice ( Fig. 5c ). Thus, improved parasite control after in vivo blockade of PD-L1 and LAG-3 was directly associated with enhanced T FH cell numbers and plasma cell differentiation.
Blockade enhances germinal-center B cells and antibodies
To formally investigate the mechanistic role of B cells and antibody responses during blockade of PD-L1 and LAG-3, we next counted and characterized total and germinal-center B cells, as well as the functional production of serum immunoglobulins to Plasmodium . For mice with matched P. yoelii infection, those that received blockade therapy with anti-PD-L1 and anti-LAG-3 had tenfold more CD19 + B220 + B cells ( Fig. 6a ), 20-fold more germinal-center B cells that stained with peanut agglutinin (PNA hi ; Fig. 6b,c ) and 30-fold more germinal-center B cells that had undergone class-switch recombination ( Fig. 6b,c ) than did control mice treated with rat IgG. Of note, the considerable expansion of the CD19 lo B220 lo PNA int subset of cells observed after combined blockade of PD-L1 and LAG-3 ( Fig. 6b ) corresponded to B cell plasmablast populations (CD19 lo B220 lo CD13 8 hi IgD − ; Fig. 5b ). Consistent with the flow cytometry data, immunostaining of cryosectioned spleens 21 d after infection showed that mice treated with combined blockade of PD-L1 and LAG-3 had qualitatively improved splenic architecture marked by preservation of IgM + B cell follicles and enhanced PNA + germinal center formation relative to that of control mice treated with rat IgG ( Supplementary Fig. 7 ). Additionally, we measured serum titers of immunoglobulins specific for the blood-stage Plasmodium antigen and human malaria vaccine 11, 41 . In line with the improved T FH cell and B cell responses, in vivo blockade of PD-L1 and LAG-3 resulted in higher titers of MSP1 19 -specific IgG than did control treatment with rat IgG ( Fig. 6d ). Notably, transfer of serum from mice that received therapy with anti-PD-L1 and anti-LAG-3 into naive mice resulted in much better control and accelerated parasite clearance after challenge with blood-stage P. yoelii parasites than did transfer of serum from mice treated with rat IgG ( Fig. 6e ). The finding that MSP1 19 -specific IgG titers were only 2.5-fold higher in blockadetreated mice than in control mice suggested that MSP1 19 -specific antibodies of other subclasses and / or antibodies specific for other blood-stage Plasmodium antigens contributed substantially to protection. Collectively, these data showed that therapeutic blockade of PD-L1 and LAG-3 during established Plasmodium blood-stage infection substantially improved the antiplasmodium humoral response through potent induction and secretion of protective antibodies.
DISCUSSION
Here we have shown that P. falciparum infection in humans was associated with more PD-1-expressing CD4 + T cells. We then showed that CD4 + T cell dysfunction, which negatively affects the induction of protective Plasmodium -specific antibody responses, was a major underlying factor for prolonged blood-stage Plasmodium infection in mice. We also found that the administration of PD-L1-and LAG-3-specific blocking antibodies markedly improved effector T cell and CD4 + T FH cell responses, as well as antibody-producing B cell responses, which resulted in a rapid decrease in parasitemia and accelerated parasite clearance. Our results are consistent with a published study showing PD-1 expression on T cells during blood-stage P. yoelii infection in mice 42 , although the functional importance of this finding was not experimentally addressed. Of relevance, biological agents targeting similar inhibitory pathways that have been designed to improve T cell responses to neoplastic disease are now in clinical trials 32, 43 . Thus, our results provide new insights into the mechanisms of parasite persistence and support the idea that alternative immune-based strategies may have clinically relevant applications in parasitic infections such as malaria.
Chronic or prolonged microbial infection and repeated antigenic stimulation are associated with functional exhaustion of CD8 + T cells in both humans 20, 21 and mice 22 -24 . Although exhaustion of CD4 + T cells may be associated with infection of humans with human immunodeficiency virus 19, 44 or hepatitis C virus 45 , as well as persistent infection of mice with Mycobacterium tuberculosis 46, 47 , direct evidence for the functional exhaustion of CD4 + T cells is lacking 48 . Blood-stage Plasmodium infection provided an opportunity for evaluating the biological importance of CD4 + T cell exhaustion, as these cells are critical for the suppression of parasite replication and full resolution of infection 10 -13 . Indeed, we observed considerable improvement in T cell function after blood-stage infection that was truncated by chloroquine treatment, and we noted functional improvement in parasite-specific T cells after combined blockade of PD-L1 and LAG-3. The latter point provided conclusive evidence that engagement of PD-L1 with its receptors (PD-1 or CD80) and LAG-3 with its ligand (MHC class II) compromised the clearance of bloodstage malaria. Blocking these interactions restored functionality to exhausted CD4 + T cells, which resulted in accelerated clearance of infection. Thus, functional exhaustion of parasite-specific CD4 + T cells had a critical role in the persistence of blood-stage Plasmodium npg infection and provided a unique target for enhancing both the control and clearance of malaria parasites.
It is well established that the axis of CD4 + T cells and antibodysecreting B cells is critical for the resolution of nonlethal blood-stage Plasmodium infection in mice and is associated with protection against severe malaria in humans. Although the precise mechanisms remain to be defined, blockade of PD-L1 and LAG-3 resulted in greater numbers and enhanced function of effector CD4 + T cells, CD4 + T FH cells and antibody-secreting B cells. Of note, modestly enhanced antibody responses have been noted after in vivo PD-1 blockade in monkeys infected with simian immunodeficiency virus 37, 38 . Here we directly demonstrated that therapeutic blockade of PD-L1 and LAG-3 during an established blood-stage Plasmodium infection resulted in ~ 50-fold more plasmablasts secreting Plasmodium-specific antibodies. Notably, therapeutic blockade of PD-L1 and LAG-3 did not prevent lethal outcomes after P. yoelii infection in mice depleted of CD4 + T cells or Aicda − / − mice in which the deletion of the immunoglobulin heavychain μ -chain secretory domain prevents antibody secretion (data not shown), which indicated that the likely targets of such blockade were CD4 + T cells and B cells.
Chronic LCMV infection drives the differentiation of virus-specific CD4 + T cells into T FH cells 40 , although the role of these cells in clearing viral infection remains unknown. Similarly, we observed the induction of T FH cell differentiation during prolonged blood-stage Plasmodium infection. We found that blockade of PD-L1 and LAG-3 further increased the frequency of T FH CD4 + T cells, which may have led to the observed enhancement of germinal-center B cell numbers, class switching to cytophilic isotypes (such as opsonizing IgG2b) in B cells, and plasmablast differentiation. Thus, the improved clinical outcome after blockade of PD-L1 and LAG-3 in mice with established malaria was directly associated with the enhancement of both cellular and humoral immunity.
Finally, we showed that enhanced control of Plasmodium infection through blockade of PD-L1 and LAG-3 could be generalized to outbred Swiss Webster mice, which suggested that therapeutic blockade of PD-L1 and LAG-3 works independently of MHC alleles or the parasite antigens or epitopes targeted by B cells and CD4 + T cells. Of note, studies of phenotypic and functional CD4 + T cell exhaustion in outbred populations are possible only with the surrogate-activationmarker approach, which allows the identification and tracking of Plasmodium-specific CD4 + T cells. Furthermore, in mice persistently infected with P. chabaudi , blockade of PD-L1 and LAG-3 mediated sterilizing clearance of blood-stage infection, which suggested that even low, subpatent parasitemia negatively affected the host ' s ability to clear the infection. This is of particular interest, as untreated humans can harbor subpatent P. falciparum infection for months or even years 15 − 17 , and Plasmodium ovale and Plasmodium vivax parasites can persist as hypnozoites in the liver for years, putting people at risk for relapses of blood-stage infection 49 . Although antigenic variation by Plasmodium contributes to immune evasion 50 , we found that dysregulation of CD4 + T cell and B cell function was another mechanism by which Plasmodium parasites evaded the host immune response.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
